By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Tibotec 

1020 Stony Hill Road
Suite 300
Yardley  Pennsylvania  19067  U.S.A.
Phone: 609-730-7500 Fax: 609-730-7501


SEARCH JOBS


Industry
Pharmaceutical






Company News
Medivir AB (MVIRb.F)’s Partner Tibotec Announced that Final SVR24 Results from Phase IIb PILLAR Study of TMC435 will be Presented at the AASLD Meeting Today 11/7/2011 7:30:41 AM
Gilead Sciences, Inc. (GILD), Johnson & Johnson (JNJ)'s Tibotec Unit to Develop Combination HIV Drug 6/28/2011 7:45:38 AM
FDA Approves Tibotec's New HIV Treatment, Edurant 5/20/2011 10:28:49 AM
Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL 3/29/2011 7:10:22 AM
Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV 2/18/2011 6:35:14 AM
Tibotec: Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 9/21/2010 9:41:05 AM
Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 6/18/2009 8:34:26 AM
//-->